marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Rhythm Pharmaceuticals Balance Sheet 2011-2024 | RYTM
Annual Balance Sheet Rhythm Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-58.8 M | -126 M | -56.7 M | - | -58.7 M | -49.5 M | -34.2 M | -6.54 M | -34.9 M | - | -7.36 M | -11.8 M | - |
Long Term Debt |
490 K | 1.26 M | 1.94 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
770 K | 684 K | 606 K | 535 K | 472 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 3.09 M | 372 K | 228 K | 311 K | - | - | 72.6 M | 52.7 M | - |
Total Current Liabilities |
55.2 M | 39.8 M | 43.4 M | 18 M | 24.4 M | 13.6 M | 6.72 M | 4.73 M | - | - | - | - | - |
Total Liabilities |
163 M | 118 M | 45.4 M | 20.5 M | 27.5 M | 14 M | 6.95 M | 5.04 M | 5.27 M | - | 75.6 M | 55.2 M | - |
Deferred Revenue |
1.29 M | 1.43 M | 7 M | - | - | - | - | - | 249 K | - | - | - | - |
Retained Earnings |
-895 M | -710 M | -529 M | -459 M | -325 M | -185 M | -110 M | -76.5 M | -50.7 M | - | -58.4 M | -37 M | - |
Total Assets |
333 M | 382 M | 330 M | 187 M | 309 M | 260 M | 152 M | 12.3 M | 37.3 M | - | 18.2 M | 18.9 M | - |
Cash and Cash Equivalents |
60.1 M | 128 M | 59.2 M | 101 M | 62.3 M | 49.5 M | 34.2 M | 6.54 M | - | - | - | - | - |
Book Value |
170 M | 264 M | 284 M | 167 M | 281 M | 246 M | 145 M | 7.3 M | 32 M | - | -57.5 M | -36.3 M | - |
Total Shareholders Equity |
170 M | 264 M | 284 M | 167 M | 281 M | 246 M | 145 M | -32.7 M | -8 M | -358 K | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Rhythm Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
4.03 M | 3.3 M | 284 K | 490 K | 692 K | 888 K | 1.08 M | 1.26 M | 73 M | - | 1.78 M | 1.94 M | 2.1 M | 2.26 M | 2.41 M | 2.55 M | 2.55 M | 2.55 M | 2.55 M | 3.09 M | 3.09 M | 3.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
211 M | 202 M | 197 M | 163 M | 157 M | 128 M | 126 M | 118 M | 108 M | - | 49.1 M | 45.4 M | 33.6 M | 36.7 M | 41.3 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 14 M | 14 M | 14 M | 14 M | 6.95 M | 6.95 M | 6.95 M | 6.95 M | 5.04 M | 5.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.43 M | 1.43 M | 1.76 M | - | 9.44 M | 7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.11 B | -1.07 B | -1.04 B | -895 M | -853 M | -809 M | -762 M | -710 M | -668 M | - | -582 M | -529 M | -486 M | -451 M | -416 M | -459 M | -459 M | -459 M | -459 M | -325 M | -325 M | -325 M | -325 M | -185 M | -185 M | -185 M | -185 M | -110 M | -110 M | -110 M | -110 M | -76.5 M | -76.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
364 M | 382 M | 259 M | 333 M | 354 M | 310 M | 346 M | 382 M | 390 M | - | 285 M | 330 M | 356 M | 388 M | 422 M | 187 M | 187 M | 187 M | 187 M | 309 M | 309 M | 309 M | 309 M | 260 M | 260 M | 260 M | 260 M | 152 M | 152 M | 152 M | 152 M | 12.3 M | 12.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
47.5 M | 162 M | 53.4 M | 60.1 M | 64.6 M | 116 M | 110 M | 128 M | 185 M | - | 78.5 M | 59.2 M | 92.4 M | 69.3 M | 87.3 M | 101 M | 101 M | 101 M | 101 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | 34.2 M | 34.2 M | 34.2 M | 34.2 M | 6.54 M | 6.54 M | - | - | 34.9 M | - | - | - | 152 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
153 M | 179 M | 61.6 M | 170 M | 197 M | 182 M | 220 M | 264 M | 281 M | - | 236 M | 284 M | 322 M | 352 M | 381 M | 167 M | 167 M | 167 M | 167 M | 281 M | 281 M | 281 M | 281 M | 246 M | 246 M | 246 M | 246 M | 145 M | 145 M | 145 M | 145 M | 7.3 M | 7.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
11.2 M | 39.3 M | 61.6 M | 170 M | 197 M | 182 M | 220 M | 264 M | 281 M | 196 M | 236 M | 284 M | 322 M | 352 M | 381 M | 167 M | 167 M | 167 M | 167 M | 281 M | 281 M | 281 M | 281 M | 246 M | 246 M | 246 M | 246 M | 145 M | 145 M | 145 M | 145 M | -32.7 M | -32.7 M | - | - | -8 M | - | - | - | -358 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency